Sanyou Bio and FatiAbGen Form Strategic Alliance to Enhance Global Biopharma Innovations

Strategic Partnership Between Sanyou Bio and FatiAbGen

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and South Korea's FatiAbGen Co., Ltd. have recently formalized a significant partnership that is set to reshape the landscape of the global biopharma market. Announced on November 27, 2025, the agreement involves a comprehensive strategic collaboration that targets several key areas: project development, exclusive representation in the Korean market, and the expansion of their global footprint.

This partnership is strategically designed to harness the strengths of both companies. Sanyou Bio brings to the table its cutting-edge AI-powered drug discovery platform, known as AI-STAL, which is recognized worldwide for its innovative capabilities. Meanwhile, FatiAbGen contributes its strong local market presence in South Korea, creating a synergistic relationship that aims to amplify growth not only in Korea but also throughout Europe and beyond.

Key Components of the Strategic Alliance

The partnership is characterized by a three-pronged cooperation framework, which is outlined as follows:
1. Joint Research and Development: The two firms will engage in concerted R&D efforts focused on a specific drug discovery project, laying the groundwork for groundbreaking innovations in biopharmaceuticals.
2. Exclusive Representation: FatiAbGen will assume the role of Sanyou Bio’s official partner in Korea, representing the latter's comprehensive drug discovery services and products, particularly those that leverage the AI-STAL platform.
3. Global Market Expansion: Both companies will collaborate to integrate their global resources, focusing particularly on expanding into the international biopharmaceutical market. This includes providing world-class R&D solutions to overseas drug developers, particularly in Europe.

In a move to solidify the partnership, members of the FatiAbGen team were invited to visit Sanyou Bio’s R&D facilities post-signing ceremony. This visit included a specialized training program designed to deepen their understanding of Sanyou’s service offerings and advanced technologies. This initiative will empower FatiAbGen to deliver informed support to Korean clients effectively.

Leadership Insights

JayJay Lee, CEO of FatiAbGen, expressed enthusiasm about the collaboration, highlighting it as a prestigious alliance with a pioneer in drug discovery. He noted that Sanyou Bio’s advanced technology platform effectively addresses existing gaps within the early-stage research and development sector faced by various biotech companies in Korea. The partnership aims to introduce top-tier R&D capabilities to the region, accelerate innovation, and enhance the global competitiveness of new drugs produced locally.

Dr. Guojun Lang, CEO of Sanyou Bio, also emphasized the importance of this partnership in the context of Sanyou's globalization strategy, recognizing FatiAbGen's local expertise and professionalism as vital assets that underpin their trust-based relationship. He expressed confidence that by integrating Sanyou's innovative drug discovery model with localized services from FatiAbGen, they would be well-equipped to swiftly meet the needs of Korean clients and contribute to a thriving regional innovation ecosystem, ultimately benefiting patients at a global level.

Conclusion

This strategic alliance marks a pivotal advancement in Sanyou Bio's plans for global expansion, signifying both companies' unwavering dedication to mutual growth. With a shared vision to empower local partners and spearhead a new wave of biopharmaceutical innovation, this partnership looks set to reshape the future of drug discovery and development, thereby offering new hope to patients worldwide.

About The Companies

FatiAbGen

FatiAbGen specializes in identifying and developing innovative monoclonal antibody therapies aimed at treating a variety of conditions including cancers and infectious diseases. The company is committed to pursuing open innovation through external collaborations to enhance its platform technologies and pipelines, aspiring to attain global leadership in its field.

Sanyou Bio

Founded with the mission to facilitate innovative biologics solutions, Sanyou Bio is a highly-regarded biopharmaceutical enterprise known for its advanced technologies and comprehensive R&D model. With a vast portfolio that includes the Super-Trillion Antibody Library, Sanyou Bio aims to establish itself as a leading global hub for original drug innovation, supported by extensive facilities and networks across major global markets.